한국어
미제공
과학 프로그램 1 일 차
English
한국어
미제공
Explore the Agenda
7:45 am Check-In & Morning Coffee
9:05 am Chair’s Opening Remarks
Navigating the Design & Clinical Translation of Costimulatory T-Cell Engagers to Improve Response Rates Whilst Maintaining Safety
9:15 am Optimizing Strategy for 4-1BB Costimulatory Bispecifics to Maximize Anti-Tumor Effects While Managing Historical 4-1BB Safety Challenges
- Exploring BH3120, a bivalent bispecific antibody generated by Pentambody® platform targeting 4-1BB and PD-L1 simultaneously, with monovalent anti-4-1BB arm (moderate affinity) and anti-PD-L1 arm (high affinity)
- Discussing how in preclinical evaluations, BH3120 demonstrated a favorable safety profile with low risk of hepatotoxicity and robust antitumor activity across multiple tumor models, with enhanced activity observed in combination with PD-1 blockade
- Outlining how early clinical results indicate a favorable safety profile by mitigating the risk of hepatotoxicity and providing initial evidence of antitumor activity across a range of tumor types
9:45 am Optimizing T-Cell Engaging Therapies from Preclinical Study to Human Clinical Trials: Conditional Activation of T-Cells in the Tumor Microenvironment by a Novel 4-1BB T-Cell Engaging BsAb (Grabody T)
- Outlining the Grabody T platform, a clinically validated 4-1BB bispecific antibody approach to overcoming liver toxicity
- Unveiling how the targeted activation of Grabody T exhibits TAA-dependent 4-1BB activation and strong in vivo efficacy
- Examining the promising clinical activity and favorable safety profile across the Grabody T pipeline (Givastomig, Ragistomig, and YH32367)
10:15 am Refreshment Break
10:45 am Topic-Focused Networking
Experience a structured networking format designed to help broaden scientific insights and connections across the ADC, Bispecific, and TPD communities.
The room will be split into five unique groups by area of content expertise – ADC Discovery, ADC Preclinical & Clinical Development, ADC Manufacturing, Bispecific Discovery & Development, TPD Discovery & Development – so attendees can select the group(s) that they would like join.
This dynamic rotational session gives participants the opportunity to meet peers with shared interests, discuss common challenges and begin to form collaborations to support objectives. Through a series of short introductory high impact conversations, attendees can also rotate within groups, ensuring networking with a diverse mix of experts.
Advancing Multispecific Antibody Design to Deepen Response Rate, Prevent Antigen Escape & Tackle Resistance
11:30 am Engineering Affinity Windows to Balance Potency, Safety & Durability in Bispecifics & T-Cell Engagers
- Designing optimal affinity windows across tumor and CD3 arms to drive effective synapse formation, while avoiding excessive T-cell activation and offtumor toxicity
- Understanding how affinity tuning influences serial killing, T-cell exhaustion, and durability of the response, particularly in solid tumor settings
- Applying affinity engineering strategies early in bispecific and T-cell engager design to improve clinical predictability and reduce downstream safety and development risk
12:00 pm Adimab’s Engineering-Driven Toolkit for Next-Generation T-Cell Engagers
- Introducing innovative heterodimerization designs, advanced antibody discovery workflows, and refined CD3 binding lineages
- Showcasing seamless platforms for T-cell engager formatting, production, and characterization
- Highlighting how engineering-first approaches drive faster development of superior TCE candidates for partners
12:30 pm T‑Cell Redirecting Therapies: Delivering Deeper & Broader Clinical Impact
- Exploring how T‑cell engagers (TcEs) are a powerful next-generation immunotherapy that reprogram “cold” tumors into “hot” tumors by redirecting T-cells toward tumor antigens
- Discussing how Boehringer Ingelheim is advancing a diverse and innovative TcE pipeline, which includes assets such as obrixtamig (DLL3/CD3), supported by cutting-edge antigen discovery platforms to identify tumor-selective targets and expand therapeutic opportunities
- Overcoming solid tumor challenges with integrated strategies that include identifying tumor-specific targets, engineering selective and potent TcE formats, applying smart combinations, and selecting the right patients to maximize clinical benefit and therapeutic window
1:00 pm Lunch
1:45 pm Meeting Booking Session
Dedicated time to have pre-scheduled 1-on-1 meetings booked through the event app, enabling deeper discussion and collaboration across the ADC, Bispecific, and TPD communities.
Pre-scheduled meetings will be available for all attendees on the main conference days from 11:30 – 15:00.
Reducing On-Target, Off-Tumor Toxicity Through Smarter Targeting Strategies & Conditional Activation
2:15 pm T-cube Platform: Enabling Safer & More Effective Next-Generation T-Cell Engagers
- Outlining how T-cube activates T-cells only in the presence of tumor-associated antigens by leveraging CD137, minimizing off-tumor activation, and reducing the risk of systemic toxicity
- Evaluating how, by avoiding direct CD3 engagement, T-cube significantly lowers the risk of cytokine release syndrome while maintaining strong antitumor activity in solid tumors
- Discussing how the modular T-cube architecture supports multiple bispecific programs -AP203, AP402, and AP601- each targeting distinct tumor biology and high-value indications
2:45 pm From Complexity to Confidence: MOA‑Reflective Bioassays & Integrated Analytics to De‑Risk Bispecific & T‑Cell Engagers
- Expand therapeutic window by MoA‑reflective potency strategy
- Outline regulatory‑ready execution with proven track record
- Explore Korea‑to‑Global acceleration through an integrated analytical toolbox
3:15 pm Novel Tetravalent Bispecific Antibody, PSMA/TRAIL‑R2 REGULGENT™, Induces Selective Tumor Cell Apoptosis Without Hepatotoxicity
- Explore how a novel tetravalent PSMA/TRAIL‑R2 bispecific antibody (REGULGENT™) was engineered to enable potent TRAIL‑R2 clustering while restricting activation to PSMA‑expressing tumor cells
- Discover how the molecule selectively induced apoptosis in PSMA/TRAIL‑R2 double‑positive tumor cells, demonstrating superior activity compared with bivalent bispecific formats
- Discuss comprehensive in vitro and in vivo studies which confirmed that REGULGENT™ achieves tumor‑specific killing without hepatotoxicity, highlighting its potential as a safer TRAIL‑R2‑targeted therapy
3:45 pm Scientific Poster Session
Contribute to the conversation and showcase your groundbreaking research in bispecific antibodies and T-cell engager drug discovery and development.
4:15 pm Bispecific Antibody Combinations for Optimized Anti-Tumor Activity in Liquid & Solid Tumors
- Co-localizing "signal 1" (TCR) and "signal 2" (co-stimulation) within the tumor microenvironment to drive optimized anti-tumor responses
- Integrating signal 3 (cytokine support) for even deeper anti-tumor responses
- Preclinical and clinical data support rational combinations with biologics in patients
4:45 pm Evolving Trends in Bispecifics: T Cell Engagers & Multispecifics
- Overview of bispecific and multispecific modalities
- Exploring the drug, clinical trial, and commercial landscape of T cell engagers
- Uncovering the drug, clinical trial, and commercial landscapes of multispecific ADCs
5:15 pm Chair’s Closing Remarks & End of Scientific Program Day One
5:20 pm Extended Poster Session
Your opportunity to view the remaining posters from within the scientific poster session